Stealth BioTherapeutics Corp

Stealth BioTherapeutics Corp (MITO) priced its initial public offering on Feb 15, 2019 at $12.00 per ADS, raising $78M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $335.3M. Jefferies was lead-left underwriter, joined by Evercore ISI, BMO Capital Markets and Nomura. WilmerHale and Walkers advised the company and Cooley advised the underwriters.

Stealth BioTherapeutics Corp is a clinical-stage biotechnology company developing therapies for diseases involving mitochondrial dysfunction, including rare primary mitochondrial diseases and common age-related conditions. Its lead product candidate, elamipretide, is being studied in several indications, starting with primary mitochondrial myopathy.

Status

IPO

Ticker

MITO

Exchange

Nasdaq Global Market

Priced

Feb 15, 2019

IPO price

$12.00 per ADS

Raised

$78M

Market cap at IPO price

$335.3M

First filed

Dec 28, 2018

Underwriters

Jefferies, Evercore ISI, BMO Capital Markets and Nomura

Company counsel

WilmerHale and Walkers

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

Cayman Islands

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.